DANCAN — Dancann Pharma A/S Income Statement
0.000.00%
Last trade - 00:00
- DKK4.25m
- DKK2.24m
- DKK6.07m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | DAS | DAS | DAS | DAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.874 | 5.71 | 6.07 |
Cost of Revenue | |||||
Gross Profit | — | — | 1.69 | 3.85 | 3.84 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.627 | 5.87 | 15.4 | 22.1 | 20.2 |
Operating Profit | -0.627 | -5.87 | -14.5 | -16.4 | -14.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.638 | -5.99 | -15.2 | -18.3 | -15.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.5 | -4.25 | -11.8 | -16.1 | -12.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.5 | -4.25 | -11.8 | -16.1 | -12.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.5 | -4.25 | -11.8 | -16.1 | -12.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.18 | -0.378 | -0.227 | -0.087 |
Dividends per Share |